HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.92
-0.29 (-2.04%)
At close: May 12, 2025, 4:00 PM
14.47
+0.55 (3.95%)
After-hours: May 12, 2025, 7:21 PM EDT
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue (ttm)
$630.20M
Revenue Growth
-24.80%
P/S Ratio
3.83
Revenue / Employee
$347,985
Employees
1,811
Market Cap
2.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HCM News
- 19 days ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 21 days ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 7 weeks ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 7 weeks ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 7 weeks ago - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewsWire
- 7 weeks ago - HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength - Benzinga
- 7 weeks ago - HUTCHMED Reports 2024 Full Year Results and Provides Business Updates - GlobeNewsWire